MNML

MNML is a synthetic biology company developing a proprietary "minimal cell" platform designed to transform the production of complex biologics and therapeutics. By engineering organisms to contain only the essential genetic material required for life, the company creates highly efficient and predictable cellular chassis for biomanufacturing. This approach aims to eliminate the metabolic burden and off-target effects associated with traditional expression systems, such as E. coli or CHO cells. The platform is intended to improve the yield, purity, and speed of development for a wide range of high-value molecules, including recombinant proteins and engineered cell therapies. Based in Brooklyn, New York, MNML is positioning its technology as a foundational tool for the next generation of precision medicine and bioproduction.